Receptor, Cannabinoid, CB2
"Receptor, Cannabinoid, CB2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of cannabinoid receptor found primarily on immune cells where it may play a role modulating release of CYTOKINES.
| Descriptor ID |
D043885
|
| MeSH Number(s) |
D12.776.543.750.695.125.200
|
| Concept/Terms |
Receptor, Cannabinoid, CB2- Receptor, Cannabinoid, CB2
- CB2 Receptor
- Receptor, CB2
- Cannabinoid Receptor CB2
- CB2, Cannabinoid Receptor
- Receptor CB2, Cannabinoid
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Cannabinoid, CB2".
Below are MeSH descriptors whose meaning is more specific than "Receptor, Cannabinoid, CB2".
This graph shows the total number of publications written about "Receptor, Cannabinoid, CB2" by people in this website by year, and whether "Receptor, Cannabinoid, CB2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, Cannabinoid, CB2" by people in Profiles.
-
Burstein S. Molecular Mechanisms for the Inflammation-Resolving Actions of Lenabasum. Mol Pharmacol. 2021 02; 99(2):125-132.
-
Szabady RL, Louissaint C, Lubben A, Xie B, Reeksting S, Tuohy C, Demma Z, Foley SE, Faherty CS, Llanos-Chea A, Olive AJ, Mrsny RJ, McCormick BA. Intestinal P-glycoprotein exports endocannabinoids to prevent inflammation and maintain homeostasis. J Clin Invest. 2018 08 31; 128(9):4044-4056.
-
Amenta PS, Jallo JI, Tuma RF, Hooper DC, Elliott MB. Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury. J Neuroinflammation. 2014 Nov 22; 11:191.
-
Tepper MA, Zurier RB, Burstein SH. Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity. Bioorg Med Chem. 2014 Jul 01; 22(13):3245-51.
-
Amenta PS, Jallo JI, Tuma RF, Elliott MB. A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury. J Neurosci Res. 2012 Dec; 90(12):2293-305.
-
Kattamuri PV, Salmonsen R, McQuain C, Burstein S, Sun H, Li G. Asymmetric synthesis of novel N-(1-phenyl-2,3-dihydroxypropyl)arachidonylamides and evaluation of their anti-inflammatory activity. Life Sci. 2013 Mar 19; 92(8-9):506-11.
-
Elliott MB, Tuma RF, Amenta PS, Barbe MF, Jallo JI. Acute effects of a selective cannabinoid-2 receptor agonist on neuroinflammation in a model of traumatic brain injury. J Neurotrauma. 2011 Jun; 28(6):973-81.
-
S?nchez AJ, Gonz?lez-P?rez P, Galve-Roperh I, Garc?a-Merino A. R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. Biochem Pharmacol. 2006 Dec 15; 72(12):1697-706.
-
Gammon CM, Freeman GM, Xie W, Xie W, Petersen SL, Wetsel WC. Regulation of gonadotropin-releasing hormone secretion by cannabinoids. Endocrinology. 2005 Oct; 146(10):4491-9.